Avandia® may reduce risk of cardiovascular disease

June 26, 2001

PHILADELPHIA -- The oral anti-diabetes drug Avandia® (rosiglitazone maleate) may decrease the risk of cardiovascular disease, the leading cause of death in the United States, according to data presented here today (June 26, 2001) at the American Diabetes Association's 61st Scientific Sessions.

Results from a study conducted at the University at Buffalo show that Avandia may have a positive effect on blood-vessel abnormalities in people at risk for cardiovascular disease and atherosclerosis, or hardening of the arteries.

Cardiovascular disease affects more than 60 million Americans, with atherosclerosis accounting for 75 percent of deaths from cardiovascular disease. People at risk for these conditions show an inability of the blood vessels to dilate properly (known as vascular reactivity) and increased arterial inflammation, based on mediators for that condition. In the UB study, Avandia was shown to improve vascular reactivity and decrease levels of mediators associated with blood-vessel inflammation.

"Avandia's effect on the prevention of atherosclerosis and its anti-inflammatory properties, as shown in this study, is an extremely important finding that may change the way we look at cardiovascular-disease prevention in the future," said Paresh Dandona, M.D., UB professor of medicine, head of the Division of Endocrinology in the UB School of Medicine and Biomedical Sciences and at Kaleida Health, and lead study investigator. "These data show Avandia has potential beyond the treatment of type 2 diabetes and may prove effective in preventing heart attack or stroke in people without diabetes."

In the UB trial, researchers studied the effects of a six-week course of therapy with Avandia on non-diabetic, obese patients at risk for cardiovascular disease. Avandia is part of a class of drugs called thiazolidinediones (TZDs, or glitazones) that treat insulin resistance, an underlying cause of type 2 diabetes and a key contributor to the development of cardiovascular disease.

Obesity often occurs in conjunction with insulin resistance. People who are insulin resistant cannot effectively use the insulin the body produces and therefore have higher than normal amounts of sugar in the blood. People with insulin resistance may also suffer several different abnormalities that contribute to their increased risk of cardiovascular disease. In addition to obesity, these metabolic abnormalities can include high blood pressure, increased blood clotting, and increased levels of proteins associated with inflammation and atherosclerosis. The study involved 11 non-diabetic obese patients who were given 4 mg of rosiglitazone daily for a period of six weeks. Fasting blood samples were obtained at 0, 1, 2, 4, 6 and 12 weeks (6 weeks after cessation of the drug). The study measured the effectiveness of Avandia in decreasing the levels of monocyte chemoattractant protein-1 (MCP-1), reactive oxygen species (ROS) and C-reactive protein (CRP), mediators of inflammatory activity associated with the development of atherosclerosis. Study endpoints included the amount of ROS generation, serum CRP and MCP-1 at the start and end of the trial. In addition, researchers measured the effect of Avandia on improving vascular reactivity.

The results showed that there was a significant fall in ROS generation by 40 percent from baseline level. There also was a fall in serum CRP by 30 percent and MCP-1 by 15 percent. Brachial arterial reactivity (dilation of the artery in the arm) increased 2.5 fold. This change implies that Avandia restores regulation of vessel responsiveness, which is frequently lost in obese insulin resistant patients and patients with type 2 diabetes. Further, this change contributes to the accelerated rates of cardiovascular illness.

"A number of studies have indicated that insulin resistance is an independent risk factor for cardiovascular disease and may actually underlie many of the metabolic risk factors predisposing patients to heart disease," said Dandona. "This research shows that we may be able to prevent the onset of atherosclerosis by targeting insulin resistance directly with Avandia in patients at high risk."
-end-
The study was funded by GlaxoSmithKline, manufacturer of Avandia.

University at Buffalo

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.